210 related articles for article (PubMed ID: 19754853)
1. Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus.
Jaumdally RJ; Goon PK; Varma C; Blann AD; Lip GY
J Intern Med; 2010 Apr; 267(4):385-93. PubMed ID: 19754853
[TBL] [Abstract][Full Text] [Related]
2. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
Nadar SK; Blann A; Beevers DG; Lip GY
J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
[TBL] [Abstract][Full Text] [Related]
3. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
Boodhwani M; Nakai Y; Voisine P; Feng J; Li J; Mieno S; Ramlawi B; Bianchi C; Laham R; Sellke FW
Circulation; 2006 Jul; 114(1 Suppl):I402-8. PubMed ID: 16820608
[TBL] [Abstract][Full Text] [Related]
4. Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors.
Deschaseaux F; Selmani Z; Falcoz PE; Mersin N; Meneveau N; Penfornis A; Kleinclauss C; Chocron S; Etievent JP; Tiberghien P; Kantelip JP; Davani S
Eur J Pharmacol; 2007 May; 562(1-2):111-8. PubMed ID: 17320859
[TBL] [Abstract][Full Text] [Related]
5. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
Lip PL; Chatterjee S; Caine GJ; Hope-Ross M; Gibson J; Blann AD; Lip GY
Br J Ophthalmol; 2004 Dec; 88(12):1543-6. PubMed ID: 15548809
[TBL] [Abstract][Full Text] [Related]
6. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.
Dogra GK; Watts GF; Chan DC; Stanton K
Diabet Med; 2005 Mar; 22(3):239-42. PubMed ID: 15717868
[TBL] [Abstract][Full Text] [Related]
7. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes.
Lee KW; Lip GY; Blann AD
Circulation; 2004 Oct; 110(16):2355-60. PubMed ID: 15302795
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Hogue JC; Lamarche B; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Mar; 57(3):380-6. PubMed ID: 18249211
[TBL] [Abstract][Full Text] [Related]
9. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
10. Systemic and intracardiac vascular endothelial growth factor and angiopoietin-1 and -2 levels in coronary artery disease: effects of angioplasty.
Jaumdally RJ; Varma C; Blann AD; MacFadyen RJ; Lip GY
Ann Med; 2007; 39(4):298-305. PubMed ID: 17558601
[TBL] [Abstract][Full Text] [Related]
11. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy.
Lee IG; Chae SL; Kim JC
Eye (Lond); 2006 May; 20(5):546-52. PubMed ID: 15905870
[TBL] [Abstract][Full Text] [Related]
12. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
14. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Konduracka E; Galicka-Latala D; Cieslik G; Rostoff P; Fedak D; Sieradzki J; Naskalski J; Piwowarska W
Diabetes Obes Metab; 2008 Sep; 10(9):719-25. PubMed ID: 17941871
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
Oikonomou E; Siasos G; Zaromitidou M; Hatzis G; Mourouzis K; Chrysohoou C; Zisimos K; Mazaris S; Tourikis P; Athanasiou D; Stefanadis C; Papavassiliou AG; Tousoulis D
Atherosclerosis; 2015 Feb; 238(2):159-64. PubMed ID: 25525743
[TBL] [Abstract][Full Text] [Related]
18. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
19. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.
David S; Kümpers P; Lukasz A; Kielstein JT; Haller H; Fliser D
J Hypertens; 2009 Aug; 27(8):1641-7. PubMed ID: 19390459
[TBL] [Abstract][Full Text] [Related]
20. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
Blanco-Colio LM; Martín-Ventura JL; Sol JM; Díaz C; Hernández G; Egido J
J Am Coll Cardiol; 2004 Apr; 43(7):1188-94. PubMed ID: 15063428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
